Vistagen Therapeutics (VTGN) Current Deferred Revenue (2020 - 2026)
Vistagen Therapeutics (VTGN) posted Current Deferred Revenue of $1.7 million for Q1 2026, down 14.46% sequentially from $2.0 million in Q4 2025, and down 33.93% YoY from $2.6 million in Q1 2025.
Vistagen Therapeutics (VTGN) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Current Deferred Revenue for 7 years, with the latest figure at $1.7 million in Q1 2026.
- Quarterly Current Deferred Revenue fell 33.93% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 33.93% YoY) and the FY2026 annual result came in at $1.7 million, down 33.93% from the prior year.
- Current Deferred Revenue declined to $1.7 million in Q1 2026 per VTGN's latest filing, from $2.0 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $2.8 million in Q1 2022 and troughed at $712300.0 in Q3 2022.
- A 5-year average of $1.7 million and a median of $1.8 million in 2023 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue sank 74.5% in 2023, then surged 227.18% in 2025.
- Over 5 years, Current Deferred Revenue stood at $712300.0 in 2022, then surged by 147.48% to $1.8 million in 2023, then surged by 42.39% to $2.5 million in 2024, then declined by 20.36% to $2.0 million in 2025, then retreated by 14.46% to $1.7 million in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.7 million, $2.0 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | Vistagen Therapeutics | 10.41 Mn | 10.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.14 Mn |
| Jun 30, 2025 | 2.51 Mn |
| Mar 31, 2025 | 2.59 Mn |
| Dec 31, 2024 | 2.51 Mn |
| Sep 30, 2024 | 2.47 Mn |
| Jun 30, 2024 | 2.30 Mn |
| Mar 31, 2024 | 791,000.00 |
| Dec 31, 2023 | 1.76 Mn |
| Sep 30, 2023 | 793,000.00 |
| Jun 30, 2023 | 714,300.00 |
| Mar 31, 2023 | 714,000.00 |
| Dec 31, 2022 | 712,300.00 |
| Sep 30, 2022 | 712,300.00 |
| Jun 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | 2.80 Mn |
| Dec 31, 2021 | 1.42 Mn |
| Sep 30, 2021 | 1.42 Mn |
| Jun 30, 2021 | 1.42 Mn |